Loading...
Medopharm — Enalapril Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #13 for Enalapril · $1.0M export value · DGFT Verified
Medopharm is the #13 Indian exporter of Enalapril with $1.0M in export value and 84 verified shipments. Medopharm holds a 0.4% market share in Enalapril exports across 12 countries. The company exports 21 pharmaceutical products worth $50.2M across 10 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED ARAB EMIRATES | $412.3K | 37 | 39.4% |
| NETHERLANDS | $278.4K | 24 | 26.6% |
| DENMARK | $114.1K | 4 | 10.9% |
| YEMEN | $53.5K | 2 | 5.1% |
| BOTSWANA | $44.9K | 1 | 4.3% |
| MALAWI | $33.5K | 3 | 3.2% |
| CAMBODIA | $30.4K | 3 | 2.9% |
| SURINAM | $21.6K | 2 | 2.1% |
| HONDURAS | $21.3K | 4 | 2.0% |
| SOLOMON ISLANDS | $14.2K | 2 | 1.4% |
Medopharm exports Enalapril to 12 countries. The largest destination is UNITED ARAB EMIRATES accounting for 39.4% of Medopharm's Enalapril shipments, followed by NETHERLANDS (26.6%) and DENMARK (10.9%). These destinations reflect Medopharm's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| IMPERIAL MEDICAL SOLUTIONS FZE | UNITED ARAB EMIRATES | $193.6K | 14 |
| M/S. IMRES | NETHERLANDS | $118.3K | 6 |
| UNICEF SUPPLY DIVISION | DENMARK | $93.4K | 3 |
| IMRES | NETHERLANDS | $72.0K | 7 |
| IMPERIAL MEDICAL SOLUTIONS FZE. | UNITED ARAB EMIRATES | $70.7K | 4 |
| CENTRAL MEDICAL STORES | BOTSWANA | $44.9K | 1 |
India exported $32.4M worth of Enalapril through 3,403 shipments from 261 suppliers to 115 countries, serving 583 buyers globally. Medopharm contributes $1.0M to this total, accounting for 0.4% of India's Enalapril exports. Medopharm ships Enalapril to 12 countries through 32 buyers.
Medopharm's average Enalapril shipment value is $12.4K per consignment, based on 84 shipments totaling $1.0M. The largest destination is UNITED ARAB EMIRATES (39.4% of Medopharm's Enalapril exports).
Medopharm ranks #13 among 261 Indian Enalapril exporters with a 0.4% market share. The top 3 exporters are IPCA LABORATORIES LIMITED ($6.2M), J B CHEMICALS AND PHARMACEUTICALS LIMITED ($4.8M), MYLAN LABORATORIES LIMITED ($4.5M). Medopharm processed 84 shipments to 12 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| ENALAPRIL MALEATE TABLETS USP 5MG (30000X 10 X 10) - NOS | $64.1K | 3 |
| ENALAPRIL MALEATE TABLETS USP 5MG (40000 | $54.4K | 2 |
| ENALAPRIL MALEATE TABLETS USP 5MG (66000 | $50.0K | 1 |
| ENALAPRIL MALEATE TABLETS USP 5MG | $44.9K | 1 |
| ENALAPRIL MALEATE TABLETS USP 5MG (20000X 10 X 10) - BOXTHD | $40.8K | 3 |
| ENALAPRIL MALEATE TABLETS USP 5MG (10000 | $39.7K | 6 |
| ENALAPRIL MALEATE TABLETS USP 10MG (5640X 100 X 10) - BOX | $37.8K | 1 |
| ENALAPRIL MALEATE TABLETS USP 5MG (25000 | $34.0K | 2 |
| ENALAPRIL MALEATE TABLETS USP 5MG 25000 |
Exporters ranked immediately above and below #13 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 10 | CADILA PHARMACEUTICALS LIMITED | $1.1M | 108 | 15 | $10.5K |
| 11 | INTAS PHARMACEUTICALS LIMITED | $1.1M | 442 | 12 | $2.5K |
| 13 | MEDOPHARM ★ | $1.0M | 84 | 12 | $12.4K |
| 14 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $1.0M | 71 |
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 474 | 13.9% |
| DELHI AIR CARGO ACC (INDEL4) | 340 | 10.0% |
| SAHAR AIR | 254 | 7.5% |
| JNPT/ NHAVA SHEVA SEA | 229 | 6.7% |
| SAHAR AIR CARGO ACC (INBOM4) | 222 | 6.5% |
| JNPT | 213 | 6.3% |
| DELHI AIR | 210 | 6.2% |
| MUNDRA SEA (INMUN1) | 124 | 3.6% |
The current geopolitical climate presents both challenges and opportunities for Indian pharmaceutical exporters like Medopharm. The Israel-Iran conflict has disrupted Red Sea shipping routes, leading to increased freight costs and extended transit times. These disruptions have particularly impacted trade corridors through the Persian Gulf and the Strait of Hormuz, vital for India's drug shipments. (pharmaceuticalcommerce.com)
Conversely, US-China trade tensions have prompted the United States to seek alternative sources for pharmaceuticals, potentially benefiting Indian exporters. However, the imposition of 100% tariffs on branded or patented pharmaceutical products by the US in October 2025 poses a significant challenge. While generic drugs may remain largely unaffected, companies like Medopharm must navigate these policy shifts carefully. (itisbl.com)
The recent India–European Union Free Trade Agreement, concluded in January 2026, offers a favorable development. The agreement eliminates tariffs on most European pharmaceutical exports to India and vice versa, potentially enhancing market access for Indian companies in the EU. (en.wikipedia.org)
India's pharmaceutical industry has made significant strides in regulatory compliance, with the country surpassing the US in the number of FDA-registered generic manufacturing sites as of 2024. This achievement reflects improved adherence to international quality standards, a critical factor for exporters like Medopharm. (business-standard.com)
However, the industry faces challenges related to quality compliance, as evidenced by incidents involving contaminated products. Maintaining rigorous quality control measures is essential for sustaining global trust and market access. (economictimes.indiatimes.com)
Medopharm exports 21 products worth $50.2M. Beyond Enalapril, top products include Amoxicillin, Metronidazole, Paracetamol, Albendazole, Ciprofloxacin. View the complete Medopharm profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Enalapril — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Medopharm's Enalapril exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Medopharm
Full Company Profile →
21 products · $50.2M total trade · 10 categories
| WORLD HEALTH ORGANIZATION,WR,YEMEN |
| YEMEN |
| $37.8K |
| 1 |
| THE MEDICAL EXPORT GROUP | NETHERLANDS | $34.5K | 4 |
| M/S. IDA TRADING MEA C/O KUEHNE + N | UNITED ARAB EMIRATES | $26.7K | 4 |
| MINISTRY OF HEALTH | MALAWI | $26.5K | 2 |
Medopharm supplies Enalapril to 32 buyers globally. The largest buyer is IMPERIAL MEDICAL SOLUTIONS FZE (UNITED ARAB EMIRATES), followed by M/S. IMRES (NETHERLANDS) and UNICEF SUPPLY DIVISION (DENMARK). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
| $33.9K |
| 2 |
| ENALAPRIL MALEATE TABLETS USP 5MG (40000X 10 X 10) -BOXTHD | $27.2K | 1 |
Medopharm exports 61 distinct Enalapril formulations including tablets, capsules, syrups, and combination drugs. The top formulation is ENALAPRIL MALEATE TABLETS USP 5MG (30000X 10 X 10) - NOS with 3 shipments worth $64.1K.
| 3 |
| $14.3K |
| 12 | BIOMATRIX HEALTHCARE PRIVATE LIMITED | $850.0K | 17 | 2 | $50.0K |
Medopharm ranks #13 among 261 Indian Enalapril exporters. Average shipment value of $12.4K compared to the market average of $124.2K. The closest competitors by value are CADILA PHARMACEUTICALS LIMITED and INTAS PHARMACEUTICALS LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 115+ countries, 583+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Medopharm.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Enalapril. For current shipment-level data, contact TransData Nexus.